ES2159734T3 - Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. - Google Patents
Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.Info
- Publication number
- ES2159734T3 ES2159734T3 ES96914621T ES96914621T ES2159734T3 ES 2159734 T3 ES2159734 T3 ES 2159734T3 ES 96914621 T ES96914621 T ES 96914621T ES 96914621 T ES96914621 T ES 96914621T ES 2159734 T3 ES2159734 T3 ES 2159734T3
- Authority
- ES
- Spain
- Prior art keywords
- represented
- derivatives
- heteroarilalquenilic
- cyclopentan
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA INVENCION SE REFIERE AL USO DE DERIVADOS DE PROSTAGLANDINAS DE TIPO F COMO HIPOTENSORES OCULARES. LOS DERIVADOS DE PGF UTILIZADOS DE ACUERDO CON LA INVENCION ESTAN REPRESENTADOS POR LA FORMULA (I), EN QUE LAS UNIONES REPRESENTADAS POR LINEAS ONDULADAS INDICAN CONFIGURACION TANTO ALFA AL} COMO BETA BE}; LOS SEGMENTOS SOMBREADOS INDICAN CONFIGURACION AL}; LOS TRIANGULOS SOLIDOS SE UTILIZAN PARA INDICAR CONFIGURACION BE}, LOS ENLACES REPRESENTADOS CON LINEA DE PUNTOS REPRESENTAN UN DOBLE ENLACE O UN ENLACE SIMPLE, R ES UN RADICAL HETEROARILO SUSTITUIDO, R SUP,1} ES HIDROGENO O UN RADICAL ALQUILO INFERIOR QUE POSEE HASTA SEIS ATOMOS DE CARBONO, X SE SELECCIONA DEL GRUPO FORMADO POR REPRESENTA DOS RADICALES HIDROGENO. CIERTOS COMPUESTOS REPRESENTADOS POR LA FORMULA (I) CONSTITUYEN OTRO ASPECTO DE LA PRESENTE INVENCION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44399295A | 1995-05-18 | 1995-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2159734T3 true ES2159734T3 (es) | 2001-10-16 |
Family
ID=23763030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96914621T Expired - Lifetime ES2159734T3 (es) | 1995-05-18 | 1996-05-14 | Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0825980B1 (es) |
JP (1) | JPH11505802A (es) |
AU (1) | AU693698B2 (es) |
CA (1) | CA2221110C (es) |
DE (1) | DE69613693T2 (es) |
ES (1) | ES2159734T3 (es) |
WO (1) | WO1996036599A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6124344A (en) * | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
AU7672096A (en) | 1995-06-07 | 1998-06-03 | Alcon Laboratories, Inc. | Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy |
US5741810A (en) * | 1996-02-29 | 1998-04-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents |
AU6545498A (en) | 1997-03-07 | 1998-09-22 | Alcon Laboratories, Inc. | 13-thia prostaglandins for use in glaucoma therapy |
ATE281432T1 (de) * | 1999-03-05 | 2004-11-15 | Univ Duke | C-16 ungesätigte fp-selektive prostaglandin analoge |
WO2000051616A1 (en) * | 1999-03-05 | 2000-09-08 | The Procter & Gamble Company | Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives |
US6395787B1 (en) | 2000-02-08 | 2002-05-28 | Allergan Sales, Inc. | Ocular hypotensive lipids |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US6248783B1 (en) * | 2000-09-20 | 2001-06-19 | Allergan Sales, Inc. | Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents |
US6291522B1 (en) * | 2000-09-27 | 2001-09-18 | Allergan Sales, Inc. | Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
US6476064B1 (en) * | 2001-06-13 | 2002-11-05 | Allergan, Inc. | Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents |
CA2466517A1 (en) | 2001-11-05 | 2003-05-15 | Allergan, Inc. | .omega.-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists |
JP2005511607A (ja) * | 2003-07-10 | 2005-04-28 | アラーガン、インコーポレイテッド | EP2受容体作動剤としてのω−シクロアルキル17−ヘテロアリールプロスタグランジンE2類似体 |
WO2007149829A2 (en) * | 2006-06-20 | 2007-12-27 | Allergan, Inc. | Therapeutic compounds |
AU2013334169B2 (en) | 2012-10-26 | 2018-03-29 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
TWI722298B (zh) | 2013-03-15 | 2021-03-21 | 美商歐樂根公司 | 含有前列醯胺之眼內植入物 |
MX2015014320A (es) * | 2013-04-12 | 2015-12-08 | Allergan Inc | Libracion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas. |
UA121108C2 (uk) * | 2013-12-13 | 2020-04-10 | Аллерган, Інк. | Тверді форми альфа,омега-дизаміщеної дигідроксициклопентильної сполуки та способи її отримання і застосування |
US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
UA120775C2 (uk) | 2015-04-30 | 2020-02-10 | Аллерган, Інк. | Косметичний спосіб та його терапевтичне застосування для зменшення об'єму жирової тканини |
US10765629B2 (en) | 2017-07-25 | 2020-09-08 | Allergan, Inc. | Solid complex, preparations and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE101342T1 (de) * | 1988-09-06 | 1994-02-15 | Kabi Pharmacia Ab | Prostaglandinderivate zur behandlung des gruenen stars oder einer okularen hypertension. |
US5352708A (en) * | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
AU665287B2 (en) * | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
-
1996
- 1996-05-14 EP EP96914621A patent/EP0825980B1/en not_active Expired - Lifetime
- 1996-05-14 CA CA002221110A patent/CA2221110C/en not_active Expired - Lifetime
- 1996-05-14 DE DE69613693T patent/DE69613693T2/de not_active Expired - Lifetime
- 1996-05-14 WO PCT/US1996/006849 patent/WO1996036599A1/en active IP Right Grant
- 1996-05-14 JP JP8534971A patent/JPH11505802A/ja not_active Ceased
- 1996-05-14 AU AU57924/96A patent/AU693698B2/en not_active Expired
- 1996-05-14 ES ES96914621T patent/ES2159734T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69613693T2 (de) | 2002-05-16 |
DE69613693D1 (de) | 2001-08-09 |
AU5792496A (en) | 1996-11-29 |
CA2221110A1 (en) | 1996-11-21 |
CA2221110C (en) | 2009-08-04 |
AU693698B2 (en) | 1998-07-02 |
EP0825980B1 (en) | 2001-07-04 |
JPH11505802A (ja) | 1999-05-25 |
WO1996036599A1 (en) | 1996-11-21 |
EP0825980A1 (en) | 1998-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2159734T3 (es) | Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. | |
MX9307940A (es) | Nuevos derivados de la imidazopiridina, proceso para su preparacion y formulaciones farmaceuticas que los incluyen | |
ES2157424T3 (es) | Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia. | |
ES2031841T3 (es) | Un procedimiento para la preparacion de derivados de 1,1-dioxido de 2-aminoalquil-1,2-benzoisotiazol-3-(2h)ona. | |
ES2161290T3 (es) | Derivados de quinazolina. | |
ES2117249T3 (es) | Derivados de 2,6-diaminopurina. | |
ES2166379T3 (es) | 2-aminotetralinas sustituidas. | |
PT92821A (pt) | Processo para a preparacao composicoes farmaceuticas para o combate de doencas do tipo psoriase, bem como doencas inflamatorias, incorporando azelastina como substancia activa | |
ES2053778T3 (es) | Procedimiento para la obtencion de derivados del tiazol. | |
ES2072263T3 (es) | Derivados de 4-aminopiridina. | |
ES2072881T3 (es) | Procedimiento de preparacion de glicoconjugados de fosforamida mostaza e isofosforamida mostaza. | |
TNSN87012A1 (fr) | Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques | |
ES2037824T3 (es) | Un procedimiento para producir un derivado de acido bifosfonico. | |
BR0008778A (pt) | Análogos de prostaglandinas seletivos para fpc16 insaturados | |
ES2029879T3 (es) | Procedimiento para producir derivados de aminas sustituidas. | |
ES2170956T3 (es) | Derivados 2-alquenilicos de acido ciclopentan(en)oico como agentes terapeuticos en el tratamiento de hipertension ocular. | |
ES2128554T3 (es) | Nuevos derivados del acido glutamico, procedimiento para su preparacion y su utilizacion como medicamentos para el aumento de la memoria y aprendizaje. | |
ES2161936T3 (es) | Benzoilguanidinas fluoradas. | |
ES2179857T3 (es) | Derivados de quinoleina sustituidos, procedimiento para su preparacion y su utilizacion. | |
ES2062407T3 (es) | Compuestos de 2-hidroxi-3-fenoxipropilamino. | |
ES2061530T3 (es) | 9-amino-1,4-etano-1,2,3,4-tetrahidroacridina y compuestos afines, intermediarios y un procedimiento para la preparacion de los mismos y su uso como medicamentos. | |
SE9604582D0 (sv) | Novel compounds | |
ES2043515B1 (es) | Procedimiento para la preparacion de nuevos derivados de 1-difenilmetilpiperazina. | |
ES2028902T3 (es) | Procedimiento de preparacion de derivados del indano. | |
ES2052391T3 (es) | Derivados de acido 5-aminosalicilico para la terapia de enfermedades inflamatorias cronicas del intestino. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 825980 Country of ref document: ES |